Overview

Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)

Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
Phase:
Phase 2
Details
Lead Sponsor:
Navidea Biopharmaceuticals